Sotera Health (NASDAQ:SHC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Sotera Health (NASDAQ:SHC) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $15.70.

A number of research firms have recently commented on SHC. Piper Sandler began coverage on shares of Sotera Health in a report on Tuesday, May 21st. They issued a “neutral” rating and a $13.00 target price for the company. Barclays increased their target price on shares of Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 target price on shares of Sotera Health in a report on Tuesday, August 6th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC raised its holdings in Sotera Health by 43.6% in the 1st quarter. Janus Henderson Group PLC now owns 14,892,868 shares of the company’s stock valued at $178,865,000 after buying an additional 4,525,056 shares during the last quarter. Vanguard Group Inc. raised its holdings in Sotera Health by 27.0% in the 1st quarter. Vanguard Group Inc. now owns 12,145,110 shares of the company’s stock valued at $145,863,000 after buying an additional 2,579,248 shares during the last quarter. Sessa Capital IM L.P. raised its holdings in Sotera Health by 7.5% in the 2nd quarter. Sessa Capital IM L.P. now owns 4,300,597 shares of the company’s stock valued at $51,048,000 after buying an additional 300,597 shares during the last quarter. Darsana Capital Partners LP bought a new position in Sotera Health in the 2nd quarter valued at approximately $29,074,000. Finally, P2 Capital Partners LLC raised its holdings in Sotera Health by 27.0% during the 4th quarter. P2 Capital Partners LLC now owns 2,350,000 shares of the company’s stock worth $39,598,000 after purchasing an additional 500,000 shares during the last quarter. Institutional investors own 91.03% of the company’s stock.

Sotera Health Trading Up 0.3 %

Shares of Sotera Health stock opened at $15.41 on Friday. The company has a market capitalization of $4.36 billion, a price-to-earnings ratio of 81.11 and a beta of 2.06. The company has a quick ratio of 2.59, a current ratio of 2.93 and a debt-to-equity ratio of 5.46. Sotera Health has a 12-month low of $10.71 and a 12-month high of $17.44. The firm’s 50-day moving average price is $13.75 and its two-hundred day moving average price is $12.79.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings data on Monday, August 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.04. The firm had revenue of $277.00 million for the quarter, compared to the consensus estimate of $266.45 million. Sotera Health had a net margin of 3.65% and a return on equity of 47.26%. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.19 earnings per share. On average, analysts forecast that Sotera Health will post 0.64 earnings per share for the current fiscal year.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.